Molecule-specific diagnosis of metabolic diseases
|
|
- Leslie Butler
- 6 years ago
- Views:
Transcription
1 Powered by Website address: Molecule-specific diagnosis of metabolic diseases Lysosomal storage diseases (LSDs) are a group of rare inherited metabolic diseases that are difficult to diagnose due to their rather unspecific clinical signs. In cooperation with the company Centogene AG, Prof. Dr. Michael Przybylski from the Steinbeis Transfer Center for Biopolymer Analysis and Biomolecular Mass Spectrometry at the University of Konstanz has developed a method that involves a novel substance class and enables the parallel measurement of enzyme activity based on fluorometry and mass spectroscopy. The method, for which the inventors have recently filed a patent, forms the basis for the development of rapid and highly specific enzyme test systems that allow the reliable and unequivocal diagnosis of diseases. In the interview with BIOPRO Baden-Württemberg, Prof. Przybylski gives us some insights into his invention. BIOPRO: Prof. Przybylski, what motivated you to develop the innovative method? Prof. Dr. Dr. Michael Przybylski works at the Steinbeis Transfer Centre for Biopolymer Analysis and Biomolecular Mass Spectrometry at the University of Konstanz Bettina Baumann / BioLAGO Przybylski: Our goal is to develop new methods for the diagnosis of lysosomal storage diseases. We also want to validate their clinical benefit and use them for diagnostic and therapeutic applications worldwide. We have developed a new substance class of substrate 1
2 derivatives for lysosomal enzymes as well as a method that is able to reliably diagnose around 40 of the or so known lysosomal storage diseases. Some of these test systems are already in the early stages of clinical testing at different clinical centres. Over the next few years, the extension of the previously available range of diagnostic methods will make a significant contribution to the development of new therapeutic substances, including for patients and diseases that cannot currently be treated. Lysosomal storage diseases manifest in a number of organs. Does this in any way influence their diagnosis? The diagnosis of LSDs is often rather difficult because the clinical signs are often vague and the different LSDs can be easily confused with each other. Differential diagnosis is difficult to the extent that doctors find it difficult to definitely diagnose the type of LSD based on clinical signs, i.e. pathological organ alterations such as the enlargement of the spleen or liver. Where tests are available, the different LSDs need to be tested individually, which requires considerable effort and can also lead to delays in diagnosis. However, the success of enzyme replacement therapies requires tests to be carried out as early as possible, as therapies are unable to reverse existing damage. If there is no test and therefore no diagnosis, effective treatment is not possible. What is the current clinical practice for diagnosing LSDs? The current standard for diagnosing LSDs is to determine the catalytical activity of lysosomal enzymes. A blood sample is mixed with a substrate derivative, which is a molecule that is specifically metabolised by the enzyme used for the diagnosis. The resulting product is measured using fluorimetry, an analytical technique for measuring the concentration of the product, from which the activity of the enzyme can then be deduced. As far as I know, you mainly use mass spectrometric methods. Can you tell me why? Yes, of course. Over the last few years, mass spectrometry-based tests have been developed for the diagnosis of 6 or 8 storage diseases. These tests use specific substrates that can only be used in mass spectrometry. It is therefore rather difficult to compare these data with those obtained using conventional fluorimetric methods. However, clinical and diagnostic screenings, which need to be carried out in order to establish and validate the new methods, rely on data that are comparable. This also applies to future serial applications. The research that you are doing in the transfer project aims to provide new perspectives for molecule-specific diagnoses and hence approaches for the development of new therapies, both in Germany and worldwide. Have your methods, for which you have recently filed 2
3 patents, already led to successful outcomes? Single blood droplets on filter paper are all that is needed for diagnosis. Bettina Baumann / BioLAGO We have succeeded in developing a new diagnostic test principle using a new substance class. Our substrate analogues allow the determination of enzyme activity using fluorimetric analysis as well as tandem mass spectrometry using one and the same substrate. The new substrate analogues contain a functional group that can be determined fluorimetrically after the substrates have been converted by the enzyme. We use an isotope-labelled variant of the enzymatic product as a standard in mass spectrometric as well as fluorimetric analyses. The isotope-labelled variant is chemically identical with the product, but has a slightly different mass, which is why mass spectrometry can definitely distinguish it from the product. The use of identical substrates for both mass spectrometric and fluorimetric analyses has the advantage that the clinical results become comparable, thus making the data highly reliable. What are your substrates exactly? The substrate analogues are novel umbelliferyl derivatives which are linked to the enzyme s normal substrate, a hydrocarbon like glucose for example. Umbelliferone is a derivative of the secondary plant substance coumarin, the only difference being that it has an additional hydroxyl group that lights up blue under UV light. This extra hydroxyl group is the reason why umbelliferyl derivatives can be used for fluorimetric measurements. In addition, these substrate analogues allow the development of methods for the simultaneous determination of multiplex enzymes (multiplex diagnostics) in one sample by using umbelliferyl derivatives with different substitutions. How do such multiplex measurements work? Multiplex diagnostics assays allow the simultaneous measurement of the activity of several enzymes, and hence the diagnosis of several LSDs, in one sample. This has previously only been possible with mass spectrometric and not fluorimetric methods. Multiplex means that several enzymatic reactions are carried out in parallel. Several substrate analogues, which are linked to different hydrocarbons, are used in a single test and each is specifically metabolised 3
4 by only one of the enzymes included in the analysis. The different enzymes lead to different products, which in turn provide information about the activity of the respective enzymes. How many enzymes can be analysed in parallel? Is there an upper limit? The number of enzymes that can be tested simultaneously is somewhat limited as they do not convert the substrates in equal measure. We therefore use enzymes with similar substrate conversion rates in one assay. The parallel measurement of different enzyme activities is of special advantage in clinical settings and also has the potential to be used for newborn screening. We can produce kits that are able to measure 5-8 enzymes simultaneously. Our patent-pending innovation relates to the multiplex determination of 20 to 25 storage diseases simultaneously. What are your future plans for the transfer project? First, we plan to develop further substrate analogues for about 20 storage diseases, validate the test systems for the diagnosis of the diseases using patient samples, and for application in clinical diagnosis. We will also compare the method with existing methods. The second part of the project focuses on the development of a method based on affinity mass spectrometry that enables the direct molecule-specific determination of the enzymes. This method measures the concentration of the enzyme directly, not indirectly by way of the concentration of its product. The method has the great advantage that it differentiates between the complete absence and presence of functionally defective enzymes, which is not possible with activity measurements. The combination of this new method with the already established enzyme activity measurement method provides information on whether an enzyme is present or defective. The development of the new affinity mass spectrometry-based method is still in its early stages. The application of the developed methods is not limited to lysosomal storage diseases and their enzymes, but can be applied to a broad range of other protein and peptide biomarkers. Further information: Prof. Dr. Dr. Michael Przybylski Steinbeis Transfer Center for Biopolymer Analysis and Biomolecular Mass Spectrometry University of Konstanz Universitätsstraße Konstanz Tel.: +49 (0)7531/ michael.przybylski(at)uni-konstanz.de Centogene AG Freiburg Business Location Center for Human Genetics Heinrich-von-Stephan-Str Freiburg office(at)centogene.com 4
5 Article 15-Apr-2013 Bettina Baumann BioLAGO BIOPRO Baden-Württemberg GmbH The article is part of the following dossiers Metabolic diseases 5
Centre for Personalised Medicine in Tübingen - developing tailor-made treatments for patients
Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/centre-for-personalised-medicine-intuebingen-developing-tailor-made-treatments-for-patients/ Centre for Personalised Medicine
More informationTRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS
TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS THE DOORS ARE OPEN: FEEL FREE TO COME IN CENTOGENE UNLOCKS THE POWER OF GENETIC INSIGHTS TO IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH GENETIC
More informationCustomer Manual. General instructions for molecular diagnostic tests
Customer Manual General instructions for molecular diagnostic tests Dear customer, CENTOGENE is a global leader in the field of genetic diagnostics for rare hereditary diseases with the largest test portfolio
More informationTrend in diagnostic biochip. Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital
Trend in diagnostic biochip development Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital Handling of the early stage is important for
More informationBiotech Patents in Europe
Biotech Patents in Europe Introduction This circular relates to biotech patent practice in Europe. It is based on our experience of drafting and prosecuting biotech applications. The circular is written
More informationUNDERSTANDING GENETIC RESEARCH AND ALTERNATING HEMIPLEGIA OF CHILDHOOD. IT ALL BEGINS WITH THE AHC PATIENT And The Scientific Process
IT ALL BEGINS WITH THE AHC PATIENT And The Scientific Process Genetic discovery AHC Patients Need Help! Researchers collect data on AHC patients (observation) Researchers interpret and evaluate data AHC
More informationA New Era of Clinical Diagnostics: How the Business Model is Changing.
A New Era of Clinical Diagnostics: How the Business Model is Changing. Nancy J Kelley, President and CEO of Nancy J Kelley & Associates Remarks to BTIG Emerging Technologies in Healthcare Diagnostics September
More informationIMPROVE SPEED AND ACCURACY OF MONOCLONAL ANTIBODY BIOANALYSIS USING NANOTECHNOLOGY AND LCMS
IMPROVE SPEED AND ACCURACY OF MONOCLONAL ANTIBODY BIOANALYSIS USING NANOTECHNOLOGY AND LCMS As scientists gain an advanced understanding of diseases at the molecular level, the biopharmaceutical industry
More informationPlant Made Biopharmaceuticals NEXT-GENERATION THERAPEUTICS FOR ORPHAN DISEASES
Plant Made Biopharmaceuticals NEXT-GENERATION THERAPEUTICS FOR ORPHAN DISEASES PLANT MADE BIOPHARMACEUTICALS: OUR ASSET, YOUR ADVANTAGE We at Greenovation work to advance the development of new treatments
More informationPatenting Personalized Medicine in the Wake of Mayo v. Prometheus. Antoinette F. Konski August 24 th, 2012
1 Patenting Personalized Medicine in the Wake of Mayo v. Prometheus Antoinette F. Konski August 24 th, 2012 2 Roadmap Supreme Court invalidates diagnostic method claims in Mayo v. Prometheus, 132 S. Ct.
More informationCeGaT: DNA and RNA sequencing specialist
Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/cegat-dna-and-rna-sequencingspecialist/ CeGaT: DNA and RNA sequencing specialist Sequencing service providers are facing
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationDIAGNOSE AND TREAT WITH ANTIBODIES THAT RECOGNIZE NATIVE HUMAN PROTEIN EPITOPES IN BLOOD AND TISSUE
DIAGNOSE AND TREAT WITH ANTIBODIES THAT RECOGNIZE NATIVE HUMAN PROTEIN EPITOPES IN BLOOD AND TISSUE EXECUTIVE SUMMARY Oncologists reviewing blood and tissue test results face the same problems: Is the
More informationCAMBRIDGE, Mass.--(BUSINESS WIRE)--
1 von 6 20.12.2016 17:44 By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes Tue 20 Dec 2016 16:43 - UK Markets are closed Press Release: Sanofi Genzyme
More informationBayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms
Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs
More informationAbout OMICS Group Conferences
About OMICS Group OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of
More informationMicrofluidics as an enabler for Medical Diagnostics
Microfluidics as an enabler for Medical Diagnostics Henne van Heeren, enablingmnt Microfluidics: The ability to create complex channel manifolds on a single substrate with no dead volume between connecting
More informationLaboratory Testing Issues for Protein C, Protein S and Antithrombin Assays
Laboratory Testing Issues for Protein C, Protein S and Antithrombin Assays Richard A. Marlar Ph.D. University of Oklahoma THSNA Meeting- Chicago, IL April 14-16, 2016 DISCLOSURE Richard A. Marlar, PhD
More informationNewborn Screening for Nine Lysosomal Storage Diseases
Newborn Screening for Nine Lysosomal Storage Diseases Michael H. Gelb, Frank Turecek, C. Ron Scott Zdenek Spacil, Brian Wolfe, Trisha Duffey, Sophie Blanchard Univ. of Washington 2004: We reported a 5-plex
More informationIntroduction to Proteomics
Introduction to Proteomics Tasso Miliotis, PhD AstraZeneca R&D Gothenburg Translational Sciences tasso.miliotis@astrazeneca.com 1 Site Management Mölndal May 2008 Outline Drug Discovery AZ R&D Sample Preparation
More informationtimstof Innovation with Integrity Powered by PASEF TIMS-QTOF MS
timstof Powered by PASEF Innovation with Integrity TIMS-QTOF MS timstof The new standard for high speed, high sensitivity shotgun proteomics The timstof Pro with PASEF technology delivers revolutionary
More informationIndustry-Academic Corporation Kyungpook National University
Industry-Academic Corporation Title (Name of Technology) Composition for Glucose Sensing Comprising of Nanofibrous Membrane and Method for Manufacturing Non-enzymatic Glucose BlOsensor Using the Same 1
More informationBIOCRATES Life Sciences AG Short Company Presentation
BIOCRATES Life Sciences AG Short Company Presentation Dr. Alexandra C. Gruber MBA MMFin Director Business Development / Marketing Austria Showcase Life Science Japan, Tokyo, December 2010 BIOCRATES Life
More informationThe Leader in AAV Gene Therapy. A Guide to AAV Gene Therapy for MPS I and II
The Leader in AAV Gene Therapy A Guide to AAV Gene Therapy for MPS I and II REGENXBIO seeks to understand the diverse perspectives of patients, caregivers and families, and to learn from their experiences
More informationOur Solutions for Protein Analysis
Our Solutions for Protein Analysis www.horibalifesciences.com info.sci@horiba.com Solutions for Protein Characterization Kinetics Proteins are involved in many critical roles in the body: Enzymes - allow
More informationWhat is the purpose of this website?
What is the purpose of this website? This website aims to explain: How it is possible for different methods to give different results for the same test on the same patient sample Why it is important to
More informationBIOO RESEARCH PRODUCTS. Alkaline Phosphatase (AP) Color Endpoint Assay Kit Manual Catalog #:
BIOO RESEARCH PRODUCTS Alkaline Phosphatase (AP) Color Endpoint Assay Kit Manual Catalog #: 3460-09 BIOO Scientific Corp. 2011 TABLE OF CONTENTS GENERAL INFORMATION... 1 Product Description... 1 Procedure
More informationMissouri s Experience with Full Population Pilot Screening for Pompe, Gaucher, Fabry and MPS-I Disorders. Utilizing Digital Microfluidics Technology
Missouri s Experience with Full Population Pilot Screening for Pompe, Gaucher, Fabry and MPS-I Disorders Utilizing Digital Microfluidics Technology Patrick Hopkins, Chief of Missouri NBS Laboratory October
More informationMulti Way Biosensors: Development and Commercialization
B2.2 Multi Way Biosensors: Development and Commercialization Zahn, Dorothea; Szeponik, Jan; Gandhi, Adrian BST Bio Sensor Technology GmbH Buchholzer Strasse 55-61, 13156 Berlin, Germany Introduction The
More informationApplicazioni biotecnologiche
Applicazioni biotecnologiche Analisi forense Sintesi di proteine ricombinanti Restriction Fragment Length Polymorphism (RFLP) Polymorphism (more fully genetic polymorphism) refers to the simultaneous occurrence
More informationAdvancing Life Sciences
Advancing Life Sciences Sweden s largest center for life sciences A national resource SciLifeLab, Science for Life Laboratory, is a Swedish national center for molecular biosciences, with the mission to
More informationMedical instrumentationi 11/19/2010
Medical instrumentationi BIOEN 302 11/19/2010 Medical instrumentation Definition: instrument for sensing, diagnostics, therapeutics or surgery of human being. 2 Medical instrumentation Definition: instrument
More informationIndustry Case Study: Expanded Access at Ultragenyx
Industry Case Study: Expanded Access at Ultragenyx Hank Mansbach, MD VP, Medical Affairs September 13, 2016 www.ultragenyx.com Introduction to Ultragenyx A clinical-stage biopharmaceutical company based
More informationCommon Patent Myths and Tips for Biomarker Inventions
Common Patent Myths and Tips for Biomarker Inventions Alice Yuen Ting Wong, Ph.D. DISCLAIMER: The information presented here is not and should not be considered to be legal advice. The information here
More informationSAMPLE. Mass Spectrometry in the Clinical Laboratory: General Principles and Guidance; Approved Guideline
Archived Document This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid as of September 2017. Because of
More informationBIOAUTOMATION, 2009, 13 (4),
Model for Quantitative Evaluation of Enzyme Replacement Treatment Radeva B. University Children s Hospital, Sofia, Bulgaria Summary: Gaucher disease is the most frequent lysosomal disorder. Its enzyme
More informationTotal RNA and DNA Purification
Total RNA and DNA Purification User Manual NucleoSpin RNA/DNA Buffer Set October 2008/ Rev. 05 MACHEREY-NAGEL MN Total RNA / DNA Purification from Tissue / Plant Protocol-at-a-glance (Rev. 05) 1 Homogenize
More informationINDUSTRY S VIEW ON THE FUTURE OF IN VITRO DIAGNOSTIC (IVD) LEGISLATION IN EUROPE. May 2013 SPECIAL REPRINT. By Jesús Rueda Rodríguez, EDMA
May 2013 SPECIAL REPRINT INDUSTRY S VIEW ON THE FUTURE OF IN VITRO DIAGNOSTIC (IVD) LEGISLATION IN EUROPE By Jesús Rueda Rodríguez, EDMA Reproduced with the kind permission of Global Regulatory Press from
More informationnanodsf 2bind: Your service provider for biophysical characterization of proteins Precisely revealing protein folding and stability
nanodsf Precisely revealing protein folding and stability 2bind: Your service provider for biophysical characterization of proteins This booklet was written and designed by 2bind 08 2015 Any reproduction
More informationWHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES.
June 2017 WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES. 3rd most populous country 50% of affected are children
More informationPresented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego
Presented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego Discuss the difference between DNA Genotyping and Genome Sequencing What makes you who you
More informationCanadian diagnostic claims where do we stand?
Canadian diagnostic claims where do we stand? November 13, 2017 Revised Chapter 17 of the Manuel of Patent Office Practice (MOPOP) released on November 10, 2017 includes a number of new sections including
More informationFRAMEWORK BRIEF. Point of Care Testing
FRAMEWORK BRIEF Point of Care Testing FRAMEWORK OVERVIEW HealthTrust Europe (HTE) has renewed the framework agreement for Point of Care Testing (POCT) equipment, consumables and related services. This
More informationGaucher Clinic 2007: Clinical trials
Gaucher Clinic 2007: Clinical trials ERT: TKT032 (Shire) ERT: TKT034 (Shire) ERT: PB-05-001 (Protalix) SRT: GENZ112638 (Genzyme) Chaperones: AT2101 (Amicus) Conventional Recombinant DNA Approach Evolution
More informationOutline. Impact on Human Diseases Basis for Molecular Assay Novel Biomarkers
MOLECULAR DIAGNOSITICS 1 Outline Concept of Molecular Diagnostics History of Molecular Diagnostics Impact on Human Diseases Basis for Molecular Assay Novel Biomarkers 2 Molecular Diagnosis Molecular diagnosis
More informationBiomolecular Characterization for Rational Drug Design. Maria João Romão
Biomolecular Characterization for Rational Drug Design Maria João Romão UCIBIO@REQUIMTE Applied Molecular Biosciences Unit Chemistry Department - FCT NOVA mjr@fct.unl.pt / http://sites.fct.unl.pt/xtal
More informationYOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING
YOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING THE NEW STANDARD OF CARE WHY GENETIC TESTING? Genetic testing makes it possible to know a priori how your patients will metabolize a specific drug. It is
More informationPROJECT GROUP FOR AUTOMATION IN MEDICINE AND BIOTECHNOLOGY IN MANNHEIM BIOPROCESS ENGINEERING
Fraunhofer Institute for Manufacturing Engineering and Automation IPA PROJECT GROUP FOR AUTOMATION IN MEDICINE AND BIOTECHNOLOGY IN MANNHEIM BIOPROCESS ENGINEERING VERGÜTUNG VON ERFINDUNGEN UND TECHNISCHEN
More informationA. Incorrect! Enzymes are not altered or consumed by the reactions they catalyze.
CLEP Biology - Problem Drill 04: Enzymes and Cellular Metabolism No. 1 of 10 1. Which of the following statements about enzymes is correct? (A) Enzymes are consumed in a reaction. (B) Enzymes act by lowering
More informationApproved by: Thomas M. Driskill, Jr. President & CEO
HAWAII HEALTH SYSTEMS C O R P O R A T I O N Touching Lives Everyday" Policies and Procedures Subject: Unlisted Laboratory Procedure Codes Quality Through Compliance Issued by: Corporate Compliance Committee
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More informationBuilding on our specialty expertise. Shire acquires Transkaryotic Therapies Inc.
Building on our specialty expertise Shire acquires Transkaryotic Therapies Inc. "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not
More informationSowa Rigpa Drug Research its scope and Challenges
Sowa Rigpa Drug Research its scope and Challenges By Tenzin Choedon Jamling PhD International Centre for Genetic Engineering and Biotechnology New Delhi Complementary Alternative medicine : Complementary
More informationStarter: Match the graph with the factors that affect enzymes. Reaction Rate. Reaction Rate. Jun 21 12:04 p.m.
Starter: Match the graph with the factors that affect enzymes Reaction Rate Reaction Rate Reaction Rate Reaction Rate Temperature ph Enzyme Concentration Substrate Concentration Jun 21 12:04 p.m. Quick
More informationProMass HR Applications!
ProMass HR Applications! ProMass HR Features Ø ProMass HR includes features for high resolution data processing. Ø ProMass HR includes the standard ProMass deconvolution algorithm as well as the full Positive
More informationThe connection between genes, proteins and metabolism CAMPBELL BIOLOGY
Lecture 6 The connection between genes, proteins and metabolism CAMPBELL BIOLOGY 1 What do genes do? What cellular processes do they affect? 1902 - Garrod described: inherited disorders of metabolism also
More informationMolecular Probes. Mitesh Shrestha
Molecular Probes Mitesh Shrestha Molecular Probes Small DNA segments (genomic DNA, cdna or synthetic oligonucleotides) or RNA segments (often synthesized on DNA template) that recognize complementary sequences
More informationRNA and DNA purification
RNA and DNA purification User manual NucleoSpin RNA/DNA Buffer Set July 2013 / Rev. 07 Protocol-at-a-glance (Rev. 07) 1 Homogenize sample NucleoSpin RNA / mirna / RNA Blood / RNA Plant, NucleoSpin RNA/Protein
More information[application note] Waters Corporation, MS Technologies Centre, Manchester, UK 2
Identification and Quantification of Diagnostics Markers and Pathway Analysis for Gaucher Disease by Means of LC/MS Hans Vissers 1, Jim Langridge 1, Hans Aerts 2 1 Waters Corporation, MS Technologies Centre,
More informationThe Future of Reimbursement for Lab Developed Mass Spec Assays
The Future of Reimbursement for Lab Developed Mass Spec Assays Charles Root, PhD CodeMap, LLC Schaumberg, IL AACC/MSSS Mass Spectrometry and Separation Sciences for Lab Medicine Oct 1 2, 2015 1 The Future
More informationDEMO DAY 6th edition of the Market Assessment Program -MAP-
DEMO DAY 6th edition of the Market Assessment Program -MAP- FutureSiSens Industry: Sensor industry Problem: current flow/leak detection sensors require high energy consumption (electrical connections)
More information6th Form Open Day 15th July 2015
6th Form Open Day 15 th July 2015 DNA is like a computer program but far, far more advanced than any software ever created. Bill Gates Welcome to the Open Day event at the Institute of Genetic Medicine
More informationUsing Ligang-Binding Assay Sensitivity for Improved Matrix Tolerance and Related Parameters by Tailored Sample Dilution.
Using Ligang-Binding Assay Sensitivity for Improved Matrix Tolerance and Related Parameters by Tailored Sample Dilution. Dr. Mark Spengler, Chimera Biotec Chimera Biotec Company Overview Bioanalytical
More informationPatenting biotechnological inventions
Patenting biotechnological inventions Izabela Milczarek, PhD, Specialist in Patents Department at Patpol Patpol - European and Polish Patent and Trade Mark Attorneys What is biotechnology? The 20 th century
More informationAutoGenomics, Inc. COMPANY PROFILE. For reprint orders, please contact:
For reprint orders, please contact: reprints@future-medicine.co.uk COMPANY PROFILE AutoGenomics, Inc. Ram Vairavan Vice President, Marketing & Business Development 2270-K, Camino Vida Roble Carlsbad, CA
More informationPatenting personalised medicines in Europe. By Christian Heubeck and Wolfgang Weiss Weickmann & Weickmann
Patenting personalised medicines in Europe By Christian Heubeck and Wolfgang Weiss Weickmann & Weickmann Engineering Chemistry Life Sciences Trademarks Designs With the power of a globally acting law firm
More informationIn Vitro Companion Diagnostic Devices
4 th of Joint Conference of Taiwan and Japan on Medical products regulation In Vitro Companion Diagnostic Devices 2016/12/7 Aoyagi Yumiko Ministry of Health, Labour and Welfare Medical Device Evaluation
More informationYour strategic partner in diagnostics innovation Immunoassays powered by Roche
Your strategic partner in diagnostics innovation Immunoassays powered by Roche We are CustomBiotech from Roche In your operations, behind your decisions, powering your products You are driving a paradigm
More informationTargeted Sequencing in the NBS Laboratory
Targeted Sequencing in the NBS Laboratory Christopher Greene, PhD Newborn Screening and Molecular Biology Branch Division of Laboratory Sciences Gene Sequencing in Public Health Newborn Screening February
More informationDifferential Diagnosis Between 3-MCC Deficiency and Holocarboxylase Synthetase Deficiency Facilitated by the Strand Clinical Exome Test
CASE STUDY Differential Diagnosis Between 3-MCC Deficiency and Holocarboxylase Synthetase Deficiency Facilitated by the Strand Clinical Exome Test Introduction Inborn errors of metabolism (IEM) are congenital
More informationthe biomarker testing laboratory
the biomarker testing laboratory RBM, the industry leader in comprehensive, multiplexed immunoassay testing services, delivers high-quality, reproducible biomarker results by industrializing the measurement
More informationASIAN PATENT ATTORNEYS ASSOCIATION Recognized Group of Korea. Report to Emerging IP Rights Committee 2012, Chiang Mai
ASIAN PATENT ATTORNEYS ASSOCIATION Recognized Group of Korea Report to Emerging IP Rights Committee 2012, Chiang Mai SPECIAL TOPIC REPORT ON Business Methods and the Laws of Nature, As Discussed by the
More informationIllumina Genome Analyzer. Progenika Experience. - Susana Catarino -
Illumina Genome Analyzer Progenika Experience - Susana Catarino - Who are we? 2000 PROGENIKA BIOPHARMA Development, production and commercialization of new genomic tools for diagnosis, prognosis and drug-response
More informationMOSAIQUES DIAGNOSTICS
MOSAIQUES DIAGNOSTICS CLINICAL PROTEOMICS IN DRUG DEVELOPMENT INFORMATION Clinical Proteomics for early and differential diagnosis FDA Letter of Support Possibilities of a companion test in Drug Development
More information23andMe Personal Genome Service (PGS) Genetic Health Risk Report Package Insert BRCA1/BRCA2 (Selected Variants)
23andMe Personal Genome Service (PGS) Genetic Health Risk Report Package Insert /BRCA2 (Selected Variants) Table of contents Indications for use Summary and explanation of the test Important considerations
More informationRNA and DNA purification
RNA and DNA purification User manual NucleoSpin RNA / DNA Buffer Set January 2018 / Rev. 10 www.mn-net.com Protocol-at-a-glance (Rev. 10) 1 Homogenize sample NucleoSpin RNA / mirna / RNA Blood / RNA Plant,
More informationThe following is an overview of diagnostic techniques for Ebola infection in humans.
IBM Deep Dive Topic 1/14/2015 Alex // operonlabs.com Diagnostics and Ebola: The following is an overview of diagnostic techniques for Ebola infection in humans. Current Status: The current status of Ebola
More informationNanthealth Patient Informed Consent
Patient Informed Consent Why am I being asked to give consent? You are being asked to sign this consent form because you want to have a molecular/genomic analysis performed to help your physician understand
More informationAdvanced Therapeutic Antibody Discovery with Multiplexed Screening
Advanced Therapeutic Antibody Discovery with Multiplexed Screening White Paper Scientists need powerful tools that can deliver results to fully understand the ability of candidate antibodies to interrupt
More informationPharmacogenetics: A SNPshot of the Future. Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001
Pharmacogenetics: A SNPshot of the Future Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001 1 I. What is pharmacogenetics? It is the study of how genetic variation affects drug response
More informationProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011
ProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011 1 Forward Looking Statement / Copyright notice / Disclaimer Forward Looking Statement This presentation contains forward-looking
More informationWorkshop Fachgruppe Affinity Mass Spectrometry
Workshop Fachgruppe Affinity Mass Spectrometry Affinity-Mass Spectrometry Applications in biochemistry, biomedicine and proteomics November 18-19 th 2010 University of Konstanz Organizers: Michael O. Glocker,
More informationSeptember 8, General Comments:
September 8, 2009 AMP Comments on the draft report from the Agency for Healthcare Research and Quality (AHRQ): AHRQ Draft Report on Quality, Regulation and Clinical Utility of Laboratorydeveloped Tests.
More informationSan Diego, February 2010 AAAS Annual Meeting
1 From Life Science to Environmental Science: Challenges and Successes of Molecular Biology in the past 30 years Teresa Lettieri European Commission Joint Research Centre; Institute for Environment and
More informationSpecific Types of Claims
Specific Types of Claims Dr. Shoichi Okuyama Okuyama & Sasajima Tokyo Japan February 2017 Kuala Lumpur Importance of having different categories Product and method What distinguishes a method from a product?
More informationCytogenetics Laboratory: Laboratory Information, Clinical Case Reports, and Proficiency Testing Participation
Cytogenetics Laboratory: Laboratory Information, Clinical Case Reports, and Proficiency Testing Participation Complete one form for each cytogenetics laboratory associated with the training program. List
More informationTECHNICAL NOTE Phosphorylation Site Specific Aptamers for Cancer Biomarker Peptide Enrichment and Detection in Mass Spectrometry Based Proteomics
TECHNICAL NOTE Phosphorylation Site Specific Aptamers for Cancer Biomarker Peptide Enrichment and Detection in Mass Spectrometry Based Proteomics INTRODUCTION The development of renewable capture reagents
More informationAlkaline Phosphatase Fluorimetric Assay Kit
Alkaline Phosphatase Fluorimetric Assay Kit Catalog No. KM0019 Detection and Quantification of Alkaline Phosphatase Concentrations in Biological Samples. Research Purposes Only. Not Intended for Diagnostic
More informationTRANSLATIONAL RESEARCH IN RARE AND NEUROMUSCULAR DISEASES - WHY DATA SHARING MATTERS. H a n n s Lochmüller, Newcastle University
TRANSLATIONAL RESEARCH IN RARE AND NEUROMUSCULAR DISEASES - WHY DATA SHARING MATTERS H a n n s Lochmüller, Newcastle University Addressing the translational pathway 2 Trials Gene identification/ pathophysiology
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationShort Title: CCI Biobank
Patient Label Stamp or letterhead of the department Patient Information Donation, Storage and Use of Biological Materials and Collection, Processing and Use of Data of the CCI Biobank, Medical Center -
More informationUp Close and Personal
Special Report Up Close and With Personal advances in genetics, a new type of medicine has emerged: one that s tailored just for you and your DNA. Could it transform the paradigm of how we treat and prevent
More informationCorporate Medical Policy
Corporate Medical Policy Proteogenomic Testing for Patients with Cancer (GPS Cancer Test) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteogenomic_testing_for_patients_with_cancer_gps_cancer_test
More informationAIT - Austrian Institute of Technology
BIOMARKER DISCOVERY, BIOINFORMATICS, AND BIOSENSOR DEVELOPMENT Technology Experience AIT Austrian Institute of Technology Low-Emission Transport AIT - Austrian Institute of Technology Energy Health & Bioresources
More informationPalladin Institute of Biochemistry (IBC), Kyiv
Palladin Institute of Biochemistry (IBC), Kyiv Technical Area: Biotechnologies, Agricultural Sciences and Medicine; Chemistry Keywords: new methods of production and practical application of biologically
More informationFrom Liquid Biopsy and FFPE Samples to Results
From Liquid Biopsy and FFPE Samples to Results Fully automated purification, reliable quantification and bisulfite conversion of cell-free circulating DNA and DNA from FFPE samples Fully automated purification,
More informationThis document is a preview generated by EVS
TECHNICAL SPECIFICATION SPÉCIFICATION TECHNIQUE TECHNISCHE SPEZIFIKATION CEN/TS 16945 May 2016 ICS 11.100.10 English Version Molecular in vitro diagnostic examinations - Specifications for pre-examination
More informationCorporate Medical Policy
Corporate Medical Policy Proteogenomic Testing for Patients with Cancer (GPS Cancer Test) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteogenomic_testing_for_patients_with_cancer_gps_cancer_test
More informationCorporate Medical Policy
Corporate Medical Policy Proteogenomic Testing for Patients with Cancer (GPS Cancer Test) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteogenomic_testing_for_patients_with_cancer_gps_cancer_test
More informationUser manual MACHEREY-NAGEL. NucleoSpin RNA/ DNA buffer set. April 2005/Rev. 02
Total RNA and DNA Purification User manual NucleoSpin RNA/ DNA buffer set April 2005/Rev. 02 MACHEREY-NAGEL MN MN Protocol at a glance (Rev. 02) Total RNA/DNA Purification from Tissue/Plant Mini NucleoSpin
More information